Moran, AE, Forouzanfar, MH, Roth, GA, et al. Temporal trends in ischemic heart disease mortality in 21 world regions, 1980–2010: the Global Burden of Disease 2010 Study. Circulation 2014;129:1483–1492.CrossRefGoogle Scholar

Lozano, R, Naghavi, M, Foreman, K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380:2095–2128.Google Scholar

Go, AS, Mozaffarian, D, Roger, VL, et al. Heart disease and stroke statistics – 2014 update: a report from the American Heart Association. Circulation 2014;129(3):399–410.Google Scholar

Lakatta, EG. Age-associated cardiovascular changes in health: impact on cardiovascular disease in older persons. Heart Failure Reviews 2002;7:29–49.Google Scholar

Rich, MW. Heart disease in the elderly. In: Rosendorff, C, ed. Essential Cardiology: Principles and Practice, Third Edition. New York: Springer, 2013:669–686.Google Scholar

D’Agostino, RB, Vasan, RS, Pencina, MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 2008;117:743–753.Google Scholar

Haffner, SM, Lehto, S, Ronnemaa, T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. New Engl J Med 1998;339:229–234.CrossRefGoogle ScholarPubMed

Kuller, LH, Arnold, AM, Psaty, BM, et al. Ten-year follow-up of subclinical cardiovascular disease and risk of coronary heart disease in the Cardiovascular Health Study. Arch Int Med 2006;166:71–78.Google Scholar

White, HD, Barbash, GI, Califf, RM, et al. Age and outcome with contemporary thrombolytic therapy: results from the GUSTO-I trial. Circulation 1996;94:1826–1833.CrossRefGoogle ScholarPubMed

Scirica, BM. Acute coronary syndrome: emerging tools for diagnosis and risk assessment. J Am Coll Cardiol 2010;55:1403–1415.Google Scholar

Eggers, KM, Venge, P, Lindahl, B, Lind, L. Cardiac troponin I levels measured with a high-sensitivity assay increase over time and are strong predictors of mortality in an elderly population. J Am Coll Cardiol 2013;61:1906–1913.Google Scholar

Thygesen, K, Alpert, JS, Jaffe, AS, et al. Third universal definition of myocardial infarction. J Am Coll Cardiol 2012;60:1581–1598.Google Scholar

O’Gara, PT, Kushner, FG, Ascheim, DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction. J Am Coll Cardiol 2013;61:e78–140.CrossRefGoogle ScholarPubMed

Amsterdam, EA, Wenger, NK, Brindis, RG, et al. 2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes. J Am Coll Cardiol 2014;64(24):e139–e228.CrossRefGoogle ScholarPubMed

ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988;332: 349–360.Google Scholar

The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345: 494–502.Google Scholar

Wiviott, SD, Braunwald, E, McCabe, CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001–2015.Google Scholar

Wallentin, L, Becker, RC, Budaj, A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045–1057.Google Scholar

Steen, H, James, S, Becker, RC, et al. Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the Prospective Randomized PLATelet Inhibition and Patient Outcomes (PLATO) trial. Circ Cardiovasc Qual Outcomes 2012;680–688.Google Scholar

Mauri, L, Kereiakes, DJ, Yeh, RW, et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med 2014;371:2155–2166.Google Scholar

Morrow, DA, Braunwald, E, Bonaca, MP, et al. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med 2012;366:1404–1413.CrossRefGoogle ScholarPubMed

The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 1998;339: 436–443.Google Scholar

Antman, EM, Cohen, M, Radley, D, et al. Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction: TIMI 11B-ESSENCE meta-analysis. Circulation 1999;100:1602–1608.CrossRefGoogle ScholarPubMed

FRagmin and Fast Revascularization during InStability in Coronary artery disease (FRISC II) Investigators. Long-term low-molecular-mass heparin in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. Lancet 1999;354: 701–707.Google Scholar

Dewilde, WJ, Oirbans, T, Verheugt, FW, et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomized, controlled trial. Lancet 2013;381:1107–1115.CrossRefGoogle ScholarPubMed

COMMIT Collaborative Group. Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005;366:1622–1632.CrossRefGoogle Scholar

ACE Inhibitor Myocardial Infarction Collaborative Group. Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. Circulation 1998;97:2202–2212.Google Scholar

Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994;343:1115–1122.Google Scholar

Ambrosioni, E, Borghi, C, Magnani, B, for the Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators. The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. N Engl J Med 1995;332:80–85.Google Scholar

The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993;342:821–828.Google Scholar

Dickstein, K, Kjekshus, J. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Lancet 2002;360:752–760.CrossRefGoogle ScholarPubMed

Pitt, B, Remme, W, Zannad, F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309–1321.CrossRefGoogle ScholarPubMed

Miettinen, TA, Pyorala, K, Olsson, AG, et al. Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: findings from the Scandinavian Simvastatin Survival Study (4S). Circulation 1997;96:4211–4218.CrossRefGoogle ScholarPubMed

Lewis, SJ, Moye, LA, Sacks, FM, et al. Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range: results of the Cholesterol and Recurrent Events (CARE) trial. Ann Intern Med 1998;129:681–689.Google Scholar

The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349–1357.Google Scholar

Shepherd, J, Blauw, GJ, Murphy, MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002;360:1623–1630.Google Scholar

Stone, NJ, Intwala, S, Katz, D. Statins in very elderly adults. J Am Geriatr Soc 2014;62:943–945.Google Scholar

Rich, MW. Aggressive lipid management in very elderly adults: less is more. J Am Geriatr Soc 2014;62:945–947.Google Scholar

Sathasivam, S. Statin induced myopathy. BMJ 2008;337:a2286.Google Scholar

Lee, DS, Markwardt, S, Goeres, L, et al. Statins and physical activity in older men: the osteoporotic fractures in men study. JAMA Intern Med 2014;174:1263–1270.Google Scholar

Golomb, BA, Evans, MA, Dimsdale, JE, et al. Effects of statins on energy and fatigue with exertion: Results from a randomized controlled trial. Arch Intern Med 2012;172:1180–1182.Google Scholar

Evans, MA, Golomb, BA. Statin-associated adverse cognitive effects: survey results from 171 patients. Pharmacotherapy 2009;29:800–811.Google Scholar

The Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO IIb) Angioplasty Substudy Investigators. A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction. N Engl J Med 1997;336:1621–1628.CrossRefGoogle Scholar

De Boer, MJ, Ottervanger, JP, van’t Hof, AW, et al. Reperfusion therapy in elderly patients with acute myocardial infarction: a randomized comparison of primary angioplasty and thrombolytic therapy. J Am Coll Cardiol 2002;39:1723–1728.CrossRefGoogle ScholarPubMed

Antman, EM, Cohen, M, Bernink, PJLM, et al. The TIMI Risk Score for unstable angina/non-ST elevation MI: a method for prognostication and therapeutic decision making. JAMA 2000;284:835–842.CrossRefGoogle Scholar

Granger, CB, Goldberg, RJ, Dabbous, O, et al. Predictors of hospital mortality in the Global Registry of Acute Coronary Events (GRACE). Arch Intern Med 2003;163:2345–2353.Google Scholar

FRagmin and Fast Revascularization during InStability in Coronary artery disease (FRISC II) Investigators. Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. Lancet 1999;354: 708–715.Google Scholar

Hochman, JS. Cardiogenic shock complicating acute myocardial infarction: expanding the paradigm. Circulation 2003;107:2998–3002.CrossRefGoogle ScholarPubMed

Hochman, JS, Sleeper, LA, White, HD, et al. for the SHOCK Investigators. One-year survival following early revascularization for cardiogenic shock. JAMA 2001;285:190–192.Google Scholar

Dzavik, V, Sleeper, LA, Cocke, TP, et al. for the SHOCK Investigators. Early revascularization is associated with improved survival in elderly patients with acute myocardial infarction complicated by cardiogenic shock: a report from the SHOCK Trial Registry. Eur Heart J 2003;24:828–837.Google Scholar

Bueno, H, Lopez-Palop, R, Perez-David, E, et al. Combined effect of age and right ventricular involvement on acute inferior myocardial infarction prognosis. Circulation 1998;98:1714–1720.Google Scholar

Hasdai, D, Topol, EJ, Califf, RM, et al. Cardiogenic shock complicating acute coronary syndromes. Lancet 2000;356:749–756.Google Scholar

Fihn, SD, Gardin, JM, Abrams, J, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease. J Am Coll Cardiol 2012;60:e44–e164.Google Scholar

James, PA, Oparil, S, Carter, BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults. JAMA 2014;311:507–520.Google Scholar

Stone, NJ, Robinson, JG, Lichtenstein, AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults. J Am Coll Cardiol 2014;63:2889–2934.Google Scholar

American Geriatrics Society Expert Panel on the Care of Older Adults with Diabetes Mellitus. Guidelines abstracted from the American Geriatrics Society guidelines for improving the care of older adults with diabetes mellitus: 2013 update. J Am Geriatrc Soc 2013;61:2020–2026.Google Scholar

Witt, BJ, Jacobsen, SJ, Weston, SA, et al. Cardiac rehabilitation after myocardial infarction in the community. J Am Coll Cardiol 2004;44:988–996.Google Scholar

American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines). ACC/AHA 2002 guidelines update for exercise testing. Circulation 2002;106:1883–1892.Google Scholar

The TIME Investigators. Trial of invasive versus medical therapy in elderly patients with chronic symptomatic coronary-artery disease (TIME): a randomised trial. Lancet 2001;358:951–957.Google Scholar

Boden, WE, O’Rourke, RA, Teo, KK, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 2007;356:1503–1516.Google Scholar

Weintraub, WS, Veledar, E, Thompson, T, Burnette, J, Jurkovitz, C, Mahoney, E. Percutaneous coronary intervention outcomes in octogenarians during the stent era (National Cardiovascular Network). Am J Cardiol 2001;88:1407–1410.Google Scholar

Alexander, KP, Anstrom, KJ, Muhlbaier, LH, et al. Outcomes of cardiac surgery in patients ≥80 years: results from the National Cardiovascular Network. J Am Coll Cardiol 2000;35:731–738.CrossRefGoogle ScholarPubMed

Newman, MF, Kirchner, JL, Phillips-Bute, B, et al. for the Neurological Outcome Research Groups and the Cardiothoracic Anesthesiology Research Endeavors Investigators. Longitudinal assessment of neurocognitive function after coronary-artery bypass surgery. N Engl J Med 2001;344:395–402.CrossRefGoogle ScholarPubMed

Yancy, CW, Jessup, M, Bozkurt, B, et al. 2013 ACCF/AHA guideline for the management of heart failure. Circulation 2013;128:e240–e327.Google ScholarPubMed

The ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker versus diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981–2997.Google Scholar

Moser, M, Hebert, PR. Prevention of disease progression, left ventricular hypertrophy and congestive heart failure in hypertension treatment trials. J Am Coll Cardiol 1996;27:1214–1218.Google Scholar

Okin, PM, Devereux, RB, Jern, S, et al. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. JAMA 2004;292:2343–2349.CrossRefGoogle ScholarPubMed

Goldman, L, Hashimoto, B, Cook, EF, Loscalzo, A. Comparative reproducibility and validity of systems for assessing cardiovascular functional class: advantages of a new specific activity scale. Circulation 1981;64:1227–1234.Google Scholar

Maisel, AS, Krishnaswamy, P, Nowak, RM, et al. for the Breathing Not Properly Multinational Study Investigators. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002;347:161–167.Google Scholar

Gaggin, HK, Mohammed, AA, Bhardwaj, A, et al. Heart failure outcomes and benefits of NT-proBNP-guided management in the elderly: Results from the Prospective, Randomized ProBNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT Study). J Cardiac Fail 2012;18:626–634.Google Scholar

Redfield, MM, Rodeheffer, RJ, Jacobsen, SJ, et al. Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol 2002;40:976–982.Google Scholar

Wang, TJ, Larson, MG, Levy, D, et al. Impact of age and sex on plasma natriuretic peptide levels in healthy adults. Am J Cardiol 2002;90:254–258.Google Scholar

Heiat, A, Gross, CP, Krumholz, HM. Representation of the elderly, women, and minorities in heart failure clinical trials. Arch Intern Med 2002;162:1682–1688.CrossRefGoogle ScholarPubMed

Rich, MW, Beckham, V, Wittenberg, C, et al. A multidisciplinary intervention to prevent the readmission of elderly patients with congestive heart failure. N Engl J Med 1995;333:1190–1195.Google Scholar

Whellan, DJ, Hasselblad, V, Peterson, E, O’Connor, CM, Schulman, KA. Meta-analysis and review of heart failure disease management randomized controlled clinical trials. Am Heart J 2005;149:722–729.Google Scholar

Ades, PA, Keteyian, SJ, Balady, GJ, et al. Cardiac rehabilitation exercise and self-care for chronic heart failure. J Am Coll Cardiol HF 2013;1(6):540–547.Google ScholarPubMed

Faris, R, Flather, M, Purcell, H, et al. Current evidence supporting the role of diuretics in heart failure: a meta analysis of randomised controlled trials. Int J Cardiol 2002;82:149–158.Google Scholar

Domanski, M, Norman, J, Pitt, B, et al. Diuretic use, progressive heart failure, and death in patients in the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol 2003;42:705–708.CrossRefGoogle ScholarPubMed

Neuberg, GW, Miller, AB, O’Connor, CM, et al. Diuretic resistance predicts mortality in patients with advanced heart failure. Am Heart J 2002;144:31–38.Google Scholar

Gheorghiade, M, Zannad, F, Sopko, G, et al. Acute heart failure syndromes: current state and framework for future research. Circulation 2005;112:3958–3968.Google Scholar

Gupta, D, Georgiopoulou, VV, Kalogeropoulos, AP, et al. Dietary sodium intake in heart failure. Circulation 2012;126:479–485.Google Scholar

Flather, MD, Yusuf, S, Kober, L, et al. for the ACEI-Inhibitor Myocardial Infarction Collaborative Group. Long-term ACEI-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. Lancet 2000;355:1575–1581.CrossRefGoogle ScholarPubMed

Garg, R, Yusuf, S for the Collaborative Group on ACE Inhibitor Trials. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA 1995;273:1450–1456.CrossRefGoogle ScholarPubMed

The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fraction. N Engl J Med 1992;327:685–691.Google Scholar

Maggioni, AP, Anand, I, Gottlieb, SO, et al. Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors. J Am Coll Cardiol 2002;40:1414–1421.Google Scholar

Granger, CB, McMurray, JJV, Yusuf, S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003;362:772–776.CrossRefGoogle ScholarPubMed

Pfeffer, MA, Swedberg, K, Granger, CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003;362:759–766.Google Scholar

Kuenzli, A, Bucher, HC, Anand, I, et al. Meta-analysis of combined therapy with angiotensin receptor antagonists versus ACE inhibitors alone in patients with heart failure. PloS One 2010;5:e9946.CrossRefGoogle ScholarPubMed

Cohn, JN, Archibald, DG, Ziesche, S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure: results of a Veterans Administration Cooperative Study. N Engl J Med 1986;314:1547–1552.Google Scholar

Cohn, JN, Johnson, G, Ziesche, S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991;325:303–310.Google Scholar

Taylor, AL, Ziesche, S, Yancy, C, et al. for the African-American Heart Failure Trial Investigators. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 2004;351:2049–2057.Google Scholar

MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999;353:2001–2007.CrossRefGoogle Scholar

Packer, M, Coats, AJS, Fowler, MB, et al. for the Carvedilol Prospective Randomized Cumulative Survival Study Group. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001;344:1651–1658.CrossRefGoogle ScholarPubMed

Deedwania, PC, Gottlieb, S, Ghali, JK, et al. Efficacy, safety and tolerability of beta-adrenergic blockade with metoprolol CR/XL in elderly patients with heart failure. Eur Heart J 2004;25:1300–1309.Google Scholar

Pitt, B, Zannad, F, Remme, WJ, et al. for the Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341:709–717.Google Scholar

Zannad, F, McMurray, JJV, Krum, H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011;364:11–21.CrossRefGoogle ScholarPubMed

Juurlink, DN, Mamdani, MM, Lee, DS, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 2004;351:543–551.Google Scholar

The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997;336:525–533.Google Scholar

Rich, MW, McSherry, F, Williford, WO, Yusuf, S, for the Digitalis Investigation Group. Effect of age on mortality, hospitalizations and response to digoxin in patients with heart failure: the DIG study. J Am Coll Cardiol 2001;38:806–813.Google Scholar

Ahmed, A, Rich, MW, Love, TE, et al. Digoxin and reduction in mortality and hospitalization in heart failure: a comprehensive post hoc analysis of the DIG trial. Eur Heart J 2006;27:178–186.Google Scholar

Massie, BN, Collins, JF, Ammon, SE, et al. Randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: the Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) Trial. Circulation 2009;119:1616–1624.Google Scholar

Homma, S, Thompson, JLP, Pullicino, PM, et al. Warfarin and aspirin in patients with heart failure and sinus rhythm. N Engl J Med 2012;366:1859–1869.Google Scholar

O’Connor, CM, Gattis, WA, Uretsky, BF, et al. Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: Insights from the Flolan International Randomized Survival Trial (FIRST). Am Heart J 1999;138:78–86.Google Scholar

Cuffe, MS, Califf, RM, Adams, KFJ, et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA 2002;287:1541–1547.Google Scholar

Publication Committee for the VMAC Investigators (Vasodilation in the Management of Acute CHF). Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA 2002;287:1531–1540.Google Scholar

O’Connor, CM, Starling, RC, Hernandez, AF, et al. Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med 2011;365:32–43.Google Scholar

Daneshvar, DA, Czer, LS, Phan, A, Trento, A, Schwarz, ER. Heart transplantation in the elderly: why cardiac transplantation does not need to be limited to younger patients but can be safely performed in patients above 65 years of age. Ann Transplant 2010;15:110–119.Google Scholar

Atluri, P, Goldstone, AB, Kobrin, DM, et al. Ventricular assist device implant in the elderly is associated with increased, but respectable risk: A multi-institutional study. Ann Thorac Surg 2013;96:141–147.Google Scholar

Kitzman, DW, Gardin, JM, Gottdiener, JS, et al. for the Cardiovascular Health Study Research Group. Importance of heart failure with preserved systolic function in patients > or = 65 years of age. Am J Cardiol 2001;87:413–419.Google Scholar

Owan, TE, Hodge, DO, Herges, RM, Jacobsen, SJ, Roger, VL, Redfield, MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006;355:251–259.Google Scholar

Bhatia, RS, Tu, JV, Lee, DS, et al. Outcome of heart failure with preserved ejection fraction in a population-based study. New Engl J Med 2006;355:260–269.CrossRefGoogle ScholarPubMed

Owan, TE, Hodge, DO, Herges, RM, et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. New Engl J Med 2006;355:251–259.Google Scholar

Meta-analysis Global Group in Chronic Heart Failure (MAGGIC). The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis. Eur Heart J 2011; doi:10.1093/eurheartj/ehr254.Google Scholar

Yusuf, S, Pfeffer, MA, Swedberg, K, et al. for the CHARM investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003;362:777–781.Google Scholar

Ahmed, A, Rich, MW, Fleg, JL, et al. Effects of digoxin on morbidity and mortality in diastolic heart failure: the Ancillary Digitalis Investigation Group Trial. Circulation 2006;114:397–403.Google Scholar

Cleland, JGF, Tendera, M, Adamus, J, et al. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 2006;27:2338–2345.Google Scholar

Massie, BM, Carson, PE, McMurray, JJ, et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 2008;359:2456–2467.Google Scholar

Van Veldhuisen, DJ, Cohen-Solal, A, Bohm, M, et al. Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction. J Am Coll Cardiol 2009;53:2150–2158.Google Scholar

Pitt, B, Pfeffer, MA, Assmann, SF, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 2014;370:1383–1392.Google Scholar

Edelmann, F, Wachter, R, Schmidt, AG, et al. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. JAMA 2013;309:781–791.Google Scholar

Redfield, MM, Chen, HH, Borlaug, BA, et al. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA 2013;309:1268–1277.Google Scholar

Zile, MR, Bourge, RC, Redfield, MM, Zhou, D, Baicu, CF, Little, WC. Randomized, double-blind, placebo-controlled study of sitaxsentan to improve impaired exercise tolerance in patients with heart failure and a preserved ejection fraction. J Am Coll Cardiol HF 2014;2:123–130.Google Scholar

Conraads, VM, Metra, M, Kamp, O, et al. Effects of long-term administration of nebivolol on the clinical symptoms, exercise capacity, and left ventricular function of patients with diastolic dysfunction: results of the ELANDD study. Eur J Heart Fail 2012;14:219–225.Google Scholar

Bristow, MR, Saxon, LA, Boehmer, J, et al. for the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Investigators. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004;350:2140–2150.Google Scholar

Cleland, JGF, Daubert, JC, Erdmann, E, et al. for the Cardiac Resynchronization-Heart Failure (CARE-HF) Study Investigators. The effect of cardiac resynchronization on morbidity and mortality in heart failure. New Engl J Med 2005;352:1539–1549.Google Scholar

Tracy, CM, Epstein, AE, Darbar, D, et al. 2012 ACCF/AHA/HRS Focused update incorporated into the ACCF/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities. Circulation 2013;127:e283–e352.Google Scholar

Cheng, YJ, Zhang, J, Li, WJ, et al. More favorable response to cardiac resynchronization therapy in women than in men. Circ Arrhythm Electrophysiol 2014;7(5):807–815.Google Scholar

Zusterzeel, R, Selzman, KA, Sanders, WE, et al. Cardiac resynchronization therapy in women: US Food and Drug Administration meta-analysis of patient-level data. JAMA Intern Med 2014;174:1340–1348.Google Scholar

Verbrugge, FH, Dupont, M, De Vusser, P, et al. Response to cardiac resynchronization therapy in elderly patients (≥70 years) and octogenarians. Eur J Heart Fail 2013;15:203–210.Google Scholar

Moss, AJ, Zareba, W, Hall, WJ, et al. for the Multicenter Automatic Defibrillator Implantation Trial II Investigators. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002;346:877–883.Google Scholar

Bardy, GH, Lee, KL, Mark, DB, et al. for the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005;352:225–237.Google Scholar

Santangeli, P, Di Biase, L, Dello Russo, A, et al. Meta-analysis: age and effectiveness of prophylactic implantable cardioverter-defibrillators. Ann Intern Med 2010;153:592–599.Google Scholar

Lampert, R, Hayes, DL, Annas, GJ, et al. HRS Expert Consensus Statement on the Management of Cardiovascular Implantable Electronic Devices (CIEDs) in patients nearing end of life or requesting withdrawal of therapy. Heart Rhythm 2010;7:1008–1026.Google Scholar

Feltner, C, Jones, CD, Cene, CW, et al. Transitional care interventions to reduce readmissions for persons with heart failure: a systematic review and meta-analysis. Ann Intern Med 2014;160:774–784.Google Scholar

Huynh, BC, Rovner, A, Rich, MW. Long-term survival in elderly patients hospitalized for heart failure: 14 year follow-up from a prospective randomized trial. Arch Intern Med 2006;166:1892–1898.Google Scholar

Whellan, DJ, Goodlin, SJ, Dickinson, MG, et al. End-of-life care in patients with heart failure. J Cardiac Failure 2014;20:121–134.Google Scholar

Otto, CM, Prendergast, B. Aortic-valve stenosis – from patients at risk to severe valve obstruction. N Engl J Med 2014;371:744–756.Google Scholar

Nishimura, RA, Otto, CM, Bonow, RO, et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease. J Am Coll Cardiol 2014;63:e57–e185.Google Scholar

Leon, MB, Smith, CR, Mack, M, et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med 2010;363:1597–1607.Google Scholar

Smith, CR, Leon, MB, Mack, MJ, et al. Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med 2011;364:2187–2198.Google Scholar

Kodali, SK, Williams, MR, Smith, CR, et al. Two-year outcomes after transcatheter or surgical aortic-valve replacement. N Engl J Med 2012;366:1686–1695.Google Scholar

Reynolds, MR, Magnuson, EA, Lei, Y, et al. Health-related quality of life after transcatheter aortic valve replacement in inoperable patients with severe aortic stenosis. Circulation 2011;124:1964–1972.Google Scholar

Lindman, BR, Alexander, KP, O’Gara, PT, Afilalo, J. Futility, benefit, and transcatheter aortic valve replacement. J Am Coll Cardiol Cardiovasc Intervent; 2014;7:707–716.CrossRefGoogle ScholarPubMed

Scognamiglio, R, Rahimtoola, SH, Fasoli, G, et al. Nifedipine in asymptomatic patients with severe aortic regurgitation and normal left ventricular function. N Engl J Med 1994;331:689–694.Google Scholar

Evangelista, A, Tornos, P, Sambola, A, et al. Long-term vasodilator therapy in patients with severe aortic regurgitation. N Engl J Med 2005;353:1342–1349.Google Scholar

Mathew, JP, Fontes, ML, Tudor, IC, et al. A multicenter risk index for atrial fibrillation after cardiac surgery. JAMA 2004;291:1720–1729.Google Scholar

Crystal, E, Connolly, SJ, Sleik, K, et al. Interventions on prevention of postoperative atrial fibrillation in patients undergoing heart surgery: a meta-analysis. Circulation 2002;106:75–80.Google Scholar

Mitchell, LB, Exner, DV, Wyse, DG, et al. Prophylactic oral amiodarone for the prevention of arrhythmias that begin early after revascularization, valve replacement, or repair – PAPABEAR: a randomized controlled trial. JAMA 2005;294:3093–3100.Google Scholar

Enriquez-Sarano, M, Avierinos, JF, Messika-Zeitoun, D, et al. Quantitative determinants of the outcome of asymptomatic mitral regurgitation. N Engl J Med 2005;352:875–883.Google Scholar

Feldman, T, Foster, E, Glower, DD, et al. Percutaneous repair or surgery for mitral regurgitation. N Engl J Med 2011;364:1395–1406.Google Scholar

Wan, B, Rahnvavardi, M, Tian, DH, et al. A meta-analysis of MitraClip system versus surgery for treatment of severe mitral regurgitation. Ann Cardiothorac Surg 2013;2:683–692.Google ScholarPubMed

Lamas, GA, Lee, KL, Silverman, R, et al. Ventricular pacing or dual-chamber pacing for sinus-node dysfunction. N Engl J Med 2002;346:1854–1862.Google Scholar

Go, AS, Hylek, EM, Phillips, KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) study. JAMA 2001;285:2370–2375.CrossRefGoogle ScholarPubMed

January, CT, Wann, LS, Alpert, JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation. J Am Coll Cardiol 2014;64(21):e1–e76.Google Scholar

Coleman, CI, Perkerson, KA, Gillespie, EL, et al. Impact of prophylactic beta blockade on post-cardiothoracic surgery length of stay and atrial fibrillation. Ann Phamacother 2004;38:2012–2016.Google Scholar

Kluger, J, White, CM. Amiodarone prevents symptomatic atrial fibrillation and reduces the risk of cerebrovascular events and ventricular tachycardia after open heart surgery: results of the Atrial Fibrillation Suppression Trial (AFIST). Card Electrophysiol Rev 2003;7:165–167.Google Scholar

Wyse, DG, Waldo, AL, DiMarco, JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002;347:1825–1833.Google Scholar

The AFFIRM Investigators. Quality of life in atrial fibrillation: the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Am Heart J 2005;149:112–120.Google Scholar

Wolf, PA, Abbott, RD, Kannel, WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991;22:983–988.Google Scholar

Gage, BF, Waterman, AD, Shannon, W, et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001;285:2864–2870.Google Scholar

Lip, GY, Nieuwlaat, R, Pisters, R, Lane, DA, Crijns, HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on Atrial Fibrillation. Chest. 2010;137:263–72.Google Scholar

Connolly, SJ, Ezekowitz, MD, Yusuf, S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139–1151.Google Scholar

Patel, MR, Mahaffey, KW, Garg, J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883–891.Google Scholar

Granger, CB, Alexander, JH, McMurray, JJV, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981–992.Google Scholar

Pisters, R, Lane, DA, Nieuwlaat, R, Vos, CB, Crijns, HJ, Lip, GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010;138:1093–1100.Google Scholar

Lane, DA, Lip, GYH. Clinician update: use of the CHA₂DS₂-VASc and HAS-BLED scores to aid decision making for thromboprophylaxis in nonvalvular atrial fibrillation. Circulation 2012;126:860–865.Google Scholar

Gage, BF, Birman-Deych, E, Kerzner, R, Radford, MJ, Nilasena, DS, Rich, MW. Incidence of intracranial hemorrhage in patients with atrial fibrillation who are prone to fall. Am J Med 2005;118:612–617.Google Scholar

Donze, J, Clair, C, Hug, B, et al. Risk of falls and major bleeds in patients on oral anticoagulation therapy. Am J Med 2012;125:773–778.Google Scholar

Sardar, P, Chatterjee, S, Chaudhari, S, Lip, GY. New oral anticoagulants in elderly adults: evidence from a meta-analysis of randomized trials. J Am Geriatr Soc 2014;62:857–864.Google Scholar

Buxton, AE, Lee, KL, Fisher, JD, et al. for the Multicenter Unsustained Tachycardia Trial Investigators. A randomized study of the prevention of sudden death in patients with coronary artery disease. N Engl J Med 1999;341:1882–1890.Google Scholar

US Census Bureau, Statistical Abstract of the United States: 2012. Table 169. Visits to Office-Based Physicians and Hospital Outpatient Departments by Diagnosis: 2003 and 2008. Health and Nutrition, page 117. Available at: www.census.gov/prod/2011pubs/12statab/health.pdf (accessed August 15, 2014).Google Scholar

Gillespie, CD, Hurvitz, KA, National Center for Chronic Disease Prevention and Health Promotion, National Center for Health Statistics. Prevalence of hypertension and controlled hypertension – United States, 2007–2010. CDC Health Disparities and Inequalities Report – United States, 2013. MMWR Supplement. 2013;62(3):144–8.Google Scholar

Vasan, RS, Larson, MG, Leip, EP, et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med. 2001;345:1291–7.Google Scholar

James, PA, Oparil, S, Carter, BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the eighth joint national committee (JNC 8). JAMA. 2014;311(5):507–20.Google Scholar

Perry, HM Jr, Davis, BR, Price, TR, et al. Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke: The systolic hypertension in the elderly program (SHEP). JAMA. 2000;824:465–71.Google Scholar

Beckett, NS, Peters, R, Fletcher, AE, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358:1887–98.Google Scholar

Laubscher, T, Regier, L, Stone, S. Hypertension in the elderly: new blood pressure targets and prescribing tips. Canadian Family Physician. 2014;60(5):453–6.Google Scholar

Sica, D. Assessment of the role of ACE inhibitors in the elderly. In: Prisant, LM, ed. Hypertension in the Elderly. Totowa, NJ: Humana Press, 2005: 321–48.Google Scholar

JNC7 Express: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Bethesda, MD: National High Blood Pressure Education Program, Department of Health and Human Services, 2003:3 (table 1).Google Scholar

McDermott, M, Hoff, F, Ferrucci, L, et al. Lower extremity ischemia, calf skeletal muscle characteristics, and functional impairment in peripheral arterial disease. J Am Ger Soc. 2007;55(3):400–406.Google Scholar

Parmenter, B, Baker, M, Barry, B, et al. Muscle strength is impaired in peripheral arterial disease and predicts over ground walking ability. Submitted to J Gerontol. 30 Jun 2014.Google Scholar

Parmenter, BJ, Raymond, J, Fiatarone Singh, M. The effect of exercise on fitness and functional outcomes in intermittent claudication: a systematic review of randomized controlled trials. Sports Med. 2013;43(6):513–552.Google Scholar

McDermott, M, Greenland, P, Liu, K, et al. Leg symptoms in peripheral arterial disease. Associated clinical characteristics and functional impairment. JAMA. 2001;286(13):1599.Google Scholar

Long, J, Modrall, J, Parker, B, Swann, A, Welborn III, M, Anthony, T. Correlation between ankle-brachial index, symptoms, and health-related quality of life in patients with peripheral vascular disease. J Vasc Surg. 2004;39:723–727.Google Scholar

Caro, J, Migliaccio-Walle, K, Ishak, K, Proskorovsky, I. The morbidity and mortality following a diagnosis of peripheral arterial disease: long-term follow-up of a large database. BMC Cardiovascular Disorders. 2005;5(14):1–8.CrossRefGoogle ScholarPubMed

Criqui, M, Deneberg, J, Langer, R, Fronek, A. The epidemiology of peripheral arterial disease: importance of identifying the population at risk. Vasc Med. 1997;2(3):221–226.Google Scholar

Kannel, W, Shurtleff, D. The Framingham Study: cigarettes and the development of intermittent claudication. Geriatrics. 1973;28(2):61–68.Google Scholar

Smith, G, Shipley, M, Rose, G. Intermittent claudication, heart disease risk factors, and mortality: the Whitehall Study. Circulation. 1990;82(6):1925–1931.Google Scholar

Anderson, J, Halperin, J, Albert, N, et al. Management of patients with peripheral artery disease ACC/AHA 2005 and 2011 guidelines. Circulation. 2013;127. doi: 10.1161/CIR.1160b1013e31828b31882aa.Google Scholar

Pradhan, A, Shrivastava, S, Cook, N, Rifai, N, Creager, M, Ridker, P. Symptomatic peripheral arterial disease in women: nontraditional biomarkers of elevated risk. Circulation. 2008;117:823–831.Google Scholar

Fowkes, F, Housley, E, Riemersma, R, et al. Smoking, lipids, glucose intolerance, and blood pressure as risk factors for peripheral atherosclerosis compared with ischemic heart disease in the Edinburgh Artery Study. Am J Epidemiol. 1992;135:331–340.Google Scholar

Subherwal, S, Patel, M, Kober, L, et al. Peripheral artery disease is a coronary heart disease risk equivalent among both men and women: results from a nationwide study. Eur J Prev Cardiol. 2014;22(3). doi: 10.1177/2047487313519344.Google Scholar

McDermott, M, Mehta, S, Ahn, H, Greenland, P. Atherosclerotic risk factors are less intensively treated in patients with peripheral arterial disease than in patients with coronary artery disease. J Gen Intern Med. 1997;12(4):209–215.Google Scholar

Criqui, M, Langer, R, Fronek, A, et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med. 1992;326:381–386.Google Scholar

Rooke, T, Hirsch, A, Misra, S, et al. ACCF/AHA focused update of the Guideline for the Management of Patients with Peripheral Artery Disease (updating the 2005 guideline). J Am Coll Cardiol. 2011;58(19):2020–2045.Google Scholar

Allison, M, Ho, E, Denenberg, J, et al. Ethnic-specific prevalence of peripheral arterial disease in the United States. Am J Prev Med. 2007;32:328–333.Google Scholar

Go, A, Mozaffarian, D, Roger, V, et al. Heart Disease and Stroke Statistics 2013 Update: a report from the American Heart Association. Circulation. 2013;127(2):e6–e245.Google Scholar

Norgren, L, Hiatt, WR, Dormandy, JA, Nehler, MR, Harris, KA, Fowkes, FGR. Inter-society consensus for the management of peripheral arterial disease. J Vasc Surg. 2007;45(1):S5–S67.Google Scholar

Eraso, L, Fukaya, E, Mohler, E, Xie, D, Sha, D, Berger, J. Peripheral arterial disease, prevalence and cumulative risk factor profile analysis. Eur J Prev Cardiol. 2014;21:704–711.Google Scholar

Hirsch, AT, Criqui, MH, Treat-Jacobson, D. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA. 2001;286(11):1317–1324.Google Scholar

Centers for Disease Control and Prevention (CDC). Lower extremity disease among persons aged > or =40 years with and without diabetes: United States, 1999–2002. MMWR. 2005;54:1158–1160.+or+=40+years+with+and+without+diabetes:+United+States,+1999–2002.+MMWR.+2005;54:1158–1160.>Google Scholar

Heald, C, Fowkes, F, Murray, G, Price, J, Ankle Brachial Index Collaboration. Risk of mortality and cardiovascular disease associated with the ankle-brachial index: systematic review. Atherosclerosis. 2006;189:61–69.CrossRefGoogle ScholarPubMed

Ankle Brachial Index Collaboration, Fowkes, FG, Murray, GD, et al. Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a meta-analysis. JAMA. 2008;300(2):197–208.Google Scholar

Criqui, M, Ninomiya, J, Fronek, A. Progression of peripheral arterial disease predicts cardiovascular disease morbidity and mortality. J Am Coll Cardiol. 2008;52(21):1736–1742.Google Scholar

Garcia, L. Epidemiology and pathophysiology of lower extremity peripheral arterial disease. J Endovasc Surg. 2006;13(S2):113–119.Google Scholar

Kroger, K, Buss, C, Renzing-Kohler, K, Santosa, F, Rudofsky, G. Segmental manifestation of peripheral atherosclerosis and its association to risk factors. VASA. 2000;29(3):199–203.Google Scholar

Van Zitteren, M, Vriens, P, Heyligers, J, et al. Self-reported symptoms on questionnaires and anatomic lesions on duplex ultrasound examinations in patients with peripheral arterial disease. J Vasc Surg. 2012;55:1025–1034.Google Scholar

Gutstein, D, Fuster, V. Pathophysiology and clinical significance of atherosclerotic plaque rupture. Cardiovasc Res. 1999;41:323–333.Google Scholar

Okura, H, Asawa, K, Kubo, T, et al. Incidence and predictors of plaque rupture in the peripheral arteries. Circ Cardiovasc Interv. 2010;3:63–70.Google Scholar

Chen, Q, Shi, Y, Wang, Y, Li, X. Patterns of disease distribution of lower extremity peripheral arterial disease. Angiology. 2015 Mar 19;66(3):211–218.Google Scholar

Brevetti, G, Schiano, V, Chiariello, M. Endothelial dysfunction: a key to the pathophysiology and natural history of peripheral arterial disease? Atherosclerosis. 2008;197:1–11.Google Scholar

O’hare, A. Management of peripheral arterial disease in chronic kidney disease. Cardiol Clin. 2005;23(3):225–236.Google Scholar

Graham, I, Daly, L, Refsum, H, et al. Plasma homocysteine as a risk factor for vascular disease: the European Concerted Action Project. JAMA. 1997;277(22):1775–1781.Google Scholar

McDermott, M, Greenland, P, Guralnik, J, et al. Inflammatory markers, D-dimer, pro-thrombotic factors, and physical activity levels in patients with peripheral arterial disease. Vascular Medicine. 2004;9(2):107–115.Google Scholar

Hirsch, A, Allison, M, Gomes, A, et al. A call to action: women and peripheral artery disease: a scientific statement from the American Heart Association. Circulation. 2012;125:1449–1472.Google Scholar

Rose, G. The diagnosis of ischaemic heart pain and intermittent claudication in field surveys. Bulletin of the World Health Organisation. 1962;27:645–658.Google Scholar

Schorr, E, Treat-Jacobson, D. Methods of symptom evaluation and their impact on peripheral artery disease (PAD) symptom prevalence: a review. Vasc Med. 2013;18:95–111.Google Scholar

McDermott, M, Mehta, S, Greenland, P. Exertional leg symptoms other than intermittent claudication are common in peripheral arterial disease. Arch Intern Med. 1999;159:387–392.Google Scholar

Au, T, Golledge, J, Walker, P, Haigh, K, Nelson, M. Peripheral arterial disease – diagnosis and management in general practice. Aust Fam Physician. 2013;42(6):397–400.Google ScholarPubMed

Haigh, K, Bingley, J, Golledge, J, Walker, P. Peripheral arterial disease – screening in general practice. Aust Fam Physician. 2013;42(6):391–395.Google Scholar

Golledge, J. Lower-limb arterial disease. Lancet. 1997;350(9089):1459–1465.Google Scholar

McDermott, M, Applegate, W, Bonds, D, et al. Ankle brachial index values, leg symptoms, and functional performance among community-dwelling older men and women in the lifestyle interventions and independence for elders study. J Am Heart Assoc. 2013;2(6):e0000257.Google Scholar

Fowkes, F, Murray, G, Butcher, I, et al. Development and validation of an ankle brachial index risk model for the prediction of cardiovascular events. Eur J Prev Cardiol. 2014;21(3):310–320.Google Scholar

Hirsch, A, Haskal, Z, Hertzer, N, et al. ACC/AHA 2005 guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): executive summary a collaborative report. J Am Coll Cardiol. 2006;47(6):1239–1312.Google Scholar

Haigh, K, Bingley, J, Golledge, J, Walker, P. Barriers to screening and diagnosis of peripheral artery disease by general practitioners. Vasc Med. 2013;18(6):325–330.Google Scholar

Jens, S, Koelemay, M, Reekers, J, Bipat, S. Diagnostic performance of computed tomography angiography and contrast-enhanced magnetic resonance angiography in patients with critical limb ischaemia and intermittent claudication: systematic review and meta-analysis. Eur Radiol. 2013;23(11):3104–3114.Google Scholar

Gardner, A, Afaq, A. Management of lower extremity peripheral arterial disease. J Cardiopulm Rehabil Prev. 2008;28(6):349–357.Google Scholar

Li, Y, Burrows, N, Gregg, E, Albright, A, Geiss, L. Declining rates of hospitalization for nontraumatic lower-extremity amputation in the diabetic population aged 40 years or older: US, 1988–2008. Diabetes Care. 2012;35(2):273–277.Google Scholar

Stratton, I, AI, A, Neil, H, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321(7258):405–412.Google Scholar

Askew, CD, Parmenter, BJ, Leight, AS, Walker, PJ, Golledge, J. Exercise prescription for patients with peripheral arterial disease and intermittent claudication: a position statement from Exercise and Sports Science Australia. Journal of Science and Medicine in Sport. 2013; http://dx.doi.org/10.1016/j.jsams.2013.10.251.Google Scholar

Parmenter, BJ, Raymond, J, Dinnen, PJ, Fiatarone Singh, MA. Systematic, A Review of randomized controlled trials: walking versus alternative exercise prescription as treatment for intermittent claudication. Atherosclerosis 2011;218(1):1–12.Google Scholar

Lauret, G, Fakhry, F, Fokkenrood, H, Hunink, M, Teijink, J, Spronk, S. Modes of exercise training for intermittent claudication. Cochrane Database Syst Rev. 2014;7;CD009638.Google Scholar

Parmenter, B, Dieberg, G, Smart, N. Meta, A Analysis of exercise training to improve health related quality of life in peripheral arterial disease. Accepted for publication in Vascular Medicine 18 Oct 2014.Google Scholar

McDermott, M, Criqui, M, Greenland, P, et al. Leg strength in peripheral arterial disease: associations with disease severity and lower-extremity performance. J Vasc Surg. 2004;39(3):523–530.Google Scholar

McDermott, M, Greenland, P, Liu, K, et al. The ankle brachial index is associated with leg function and physical activity: the Walking and Leg Circulation Study. Ann Intern Med. 2002;136(12):873–883.Google Scholar

McDermott, M, Guralnik, J, Albay, M, Bandinelli, S, Miniati, B, Ferrucci, L. Impairments of muscles and nerves associated with peripheral arterial disease and their relationship with lower extremity functioning: the InCHIANTI Study. J Am Ger Soc. 2004;52(3):405–410.Google Scholar

Gardner, A, Montgomery, P, Parker, D. Physical activity is a predictor of all-cause mortality in patients with intermittent claudication. J Vasc Surg. 2008;47(1):117–122.Google Scholar

Gardner, AW, Katzel, LI, Sorkin, JD, et al. Exercise rehabilitation improves functional outcomes and peripheral circulation in patients with intermittent claudication: a randomized controlled trial. J Americ Geriatrics Soc. 2001;49(6):755–762.Google Scholar

Leeper, N, Myers, J, Zhou, M, et al. Exercise capacity is the strongest predictor of mortality in patients with peripheral arterial disease. J Vasc Surg. 2013;57(3):728–733.Google Scholar

Askew, C, Green, S, Walker, P, et al. Skeletal muscle phenotype is associated with exercise tolerance in patients with peripheral arterial disease. J Vasc Surg. 2005;41:802–807.Google Scholar

Hiatt, W. Medical treatment of peripheral arterial disease and claudication. N Engl J Med. 2001;344:1608–1621.Google Scholar

Garg, P, Liu, K, Tian, L, et al. Physical activity during daily life and functional decline in peripheral arterial disease. Circulation. 2009;119:251–260.Google Scholar

Garg, P, Tian, L, Criqui, M, et al. Physical activity during daily life and mortality in patients with peripheral arterial disease. Circulation. 2006;114:242–248.Google Scholar

Kurvers, H, van der Graaf, Y, Blankensteijn, J, Visseren, F, Eikelboom, B, SMART Study Group. Screening for asymptomatic internal carotid artery stenosis and aneurysm of the abdominal aorta: comparing the yield between patients with manifest atherosclerosis and patients with risk factors for atherosclerosis only. J Vasc Surg. 2003;37(6):1226–1233.Google Scholar

Drachman, D.A., Swearer, J.M.. Neurological Evaluation of the Elderly Patient. In: Albert, M.L., Knoefel, J.E., eds. Clinical Neurology of Aging. 3rd Edition. New York, Oxford University Press, 2011; 41–53.Google Scholar

Sirven, J.I., Mancall, E.L.. Neurological Examination of the Older Adult. In: Sirven, J.I., Malamut, B.L., eds. Clinical Neurology of the Older Adult. 2nd Edition. Philadelphia, Lippincott Williams and Wilkins, 2008; 5–7.Google Scholar

Manini, T.M., Hong, S.L., Clark, B.C.. Aging and muscle: a neuron’s perspective. Curr Opin Clini Nutr Metab Care 2013; 16(1): 1–10.Google Scholar

Chitnus, T., Weiner, H.L.. Multiple Sclerosis in the Elderly. In: Albert, M.L., Knoefel, J.E., eds. Clinical Neurology of Aging. 3rd Edition. New York, Oxford University Press, 2011; 536–543.Google Scholar

Scalfari, A., Knappertz, V., Cutter, G., et al. Mortality in patients with multiple sclerosis. Neurology 2013; 81: 184–192.Google Scholar

Hughes, R.A., Rees, J.H.. Clinical and epidemiologic features of Guillain-Barré syndrome. The Journal of Infectious Diseases 1997; 176: S92–8.Google Scholar

Yuki, N., Hartung, H.P.. Guillain-Barré syndrome. N Engl J Med 2012; 366: 2294–2304.Google Scholar

Worms, P.M.. The epidemiology of motor neuron disease: a review of recent studies. Journal of the Neurological Sciences 2001; 191: 3–9.Google Scholar

Rowland, L.P., Shneider, N.A.. Amyotrophic lateral sclerosis. N Engl J Med 2001; 344: 1688–1700.Google Scholar

Donaghy, M.. Classification and clinical features of motor neurone diseases and motor neuropathies in adults. J. Neurol 1999; 246: 331–333Google Scholar

Sieb, J.P.. Myasthenia gravis: an update for the clinician. Clinical and Experimental Immunology 2013; 175: 408–418.Google Scholar

Drachman, D.B.. Myasthenia gravis. N Engl J Med 1994; 330: 1797–1810.Google Scholar

Bitzur, R., Cohen, H., Kamai, Y., Harats, D.. Intolerance to statins: mechanisms and management. Diabetes Care 2013; 36: S325–S330.Google Scholar

Macedo, A.F., Taylor, F.C., Casas, J.P., et al. Unintended effects of statins from observational studies in the general population: systematic review and meta-analysis. BMC Medicine 2014; 12: 51–64.Google Scholar

Mold, J.W., Vesely, S.K., Keyl, B.A.. The prevalence, predictors, and consequences of peripheral sensory neuropathy in older patients. J Am Board Fam Pract 2004; 17: 309–318.Google Scholar

Hreib, K.K., Jones, H.R.. Clinical Neurologic Evaluation. In: Jones, H.R., ed. Netter’s Neurology. New Jersey, Icon Learning Systems, 2005; 2–39.Google Scholar

Hoffman Snyder, C.R., Smith, B.E.. Common Peripheral Neuropathies in the Older Adult. In: Sirven, J.I., Malamut, B.L., eds. Clinical Neurology of the Older Adult. 2nd Edition. Philadelphia, Lippincott Williams and Wilkins, 2008; 402–419.Google Scholar

Zawora, M., Liang, T.W., Jarra, H.. Neurological Problems in the Elderly. In: Arenson, S., Busby-Whitehead, J., Brummel-Smith, K., et al., eds. Reichel’s Care of the Elderly: Clinical Aspects of Aging. 6th Edition. New York, Cambridge University Press, 2009; 140–170.Google Scholar

Centers for Disease Control and Prevention. National Diabetes Statistics Report: Estimates of Diabetes and Its Burden in the United States, 2014. Atlanta, GA: US Department of Health and Human Services; 2014. Available at: www.cdc.gov/diabetes/pubs/statsreport14/national-diabetes-report-web.pdf (accessed August 3, 2014).Google Scholar

Charnogursky, G., Lee, H., Lopez, N.. Diabetic neuropathy. Handbook of Clinical Neurology 2014; 120: 773–785.Google Scholar

Schmader, K.E.. Epidemiology and impact on quality of life of postherpetic neuralgia and painful diabetic neuropathy. Clinical Journal of Pain 2002; 18: 350–354.Google Scholar

Lacomis, D.. Small-fiber neuropathy. Muscle and Nerve 2002; 26: 173–188.Google Scholar

Brannagan, T.H., Weimer, L.H., Latov, N.. Acquired Neuropathies. In: Rowland, L.P., ed. Merritt’s Neurology. 11th Edition. Philadelphia, Lippincott Williams and Wilkins, 2005; 748–767.Google Scholar

Ghaznawi, N., Virdi, A., Dayan, A., et al. Herpes zoster ophthalmicus: comparison of disease in patients 60 years and older versus younger than 60 years. Ophthalmology 2011; 118: 2242–2250.Google Scholar

Gnann, J.W., Whitley, R.J.. Herpes zoster. N Engl J Med 2002; 347: 340–346.Google Scholar

Eldar, A.H., Chapman, J.. Guillain-Barré syndrome and other immune mediated neuropathies: diagnosis and classification. Autoimmunity Reviews 2014; 13: 525–530.Google Scholar

Mahdi-Rogers, M., Hughes, R.A.. Epidemiology of chronic inflammatory neuropathies in southeast England. European Journal of Neurology 2014; 21: 28–33.Google Scholar

Lijima, M., Koike, H., Nattori, N., et al. Prevalence and incidence rates of chronic inflammatory demyelinating polyneuropathy in the Japanese population. J Neurol Neurosurgery Psychiatry 2008; 79(9): 1040–1043.Google Scholar

Rigler, S.K.. Alcoholism in the elderly. American Family Physician 2000; 61: 1710–1716.Google Scholar

Mellion, M., Gilchrist, J.M., De La Monte, S.. Alcohol-related peripheral neuropathy: nutritional, toxic, or both? Muscle and Nerve 2011; 43: 309–316.Google Scholar

Kumar, N.. Neurologic aspects of cobalamin (B12) deficiency. Handbook of Clinical Neurology 2014; 120: 915–926.Google Scholar

Nemni, R., Gerosa, E., Piccolo, G., Merlinii, G.. Neuropathies associated with monoclonal Gammopathies. Haematologica 1994; 79: 557–566.Google Scholar

Pop-Busui, R., Roberts, L., Pennathur, S., et al. The management of diabetic neuropathy in CKD. Am J Kidney Dis 2010; 55: 365–385Google Scholar

Dworkin, R.H., O’Connor, A.B., Backonja, M., et al. Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain 2007; 132: 237–251.Google Scholar

Laccheo, I., Ablah, E., Heinrichs, R., et al. Assessment of quality of life among the elderly with epilepsy. Epilepsy Behav 2008; 12: 257–261.Google Scholar

Stephen, L.J., Brodie, M.J.. Epilepsy in elderly people. Lancet 2000; 355: 1441–1446.Google Scholar

Leppik, I.E., Birnbaum, A.K.. Epilepsy in the elderly. Annals of the New York Academy of Sciences 2010; 1184: 208–224.Google Scholar

Ramsay, R.E., Rowan, A.J., Pryor, F.M.. Special considerations in treating the elderly patient with epilepsy. Neurology 2004; 62: S24–9.Google Scholar

Huying, F., Limpe, S., Werhahn, K.J.. Antiepileptic drug use in nursing home residents: a cross-sectional, regional study. Seizure 2006; 15: 194–197Google Scholar

Hardie, N.A., Garrard, J., Gross, C.R., et al. The validity of epilepsy or seizure documentation in nursing homes. Epilepsy Research 2007; 74: 171–175.Google Scholar

Brodie, M.J., Kelly, K., Stephen, L.J.. Prospective adults with new antiepileptic drugs in focal epilepsy: insights into population responses? Epilepsy and Behavior 2014; 31: 73–76.Google Scholar

Wallace, H., Shorwon, S., Tallis, R.. Age-specific incidence and prevalence rates of treated epilepsy in an unselected population of 2,052,922 and age-specific fertility rates of women with epilepsy. Lancet 1998; 352: 1970–73.Google Scholar

Bladin, C.F., Alexandrov, A.V., Bellavance, A., et al. Seizures after stroke: a prospective multicenter study. Arch Neurol 2000; 57: 1617–1622.Google Scholar

Brodie, M.J., Elder, A.T., Kwan, P.. Epilepsy in later life. Lancet Neurol 2009; 8: 1019–30.Google Scholar

Imfeld, P., Bodmer, M., Schuerch, M., et al. Seizures in patients with Alzheimer’s disease or vascular dementia: a population-based nested case control analysis. Epilepsia 2013; 54: 700–707.Google Scholar

Irizarry, M.C., Jin, S., He, F., et al. Incidence of new-onset seizures in mild to moderate Alzheimer disease. Arch Neurol 2012; 69: 368–372.Google Scholar

Sherzai, D., Losey, T., Vega, S., Sherzai, A.. Seizures and dementia in the elderly: nationwide inpatient sample 1999–2008. Epilepsy and Behavior 2014; 36: 53–56.Google Scholar

Vossel, K.A., Beagle, A.J., Rabinovici, G.D., et al. Seizures and epileptiform activity in the early stages of Alzheimer disease. JAMA Neurol 2013; 70: 1158–1166.Google Scholar

Meierkord, H., Holtkamp, M.. Non-convulsive status epilepticus in adults: clinical forms and treatment. Lancet Neurol 2007; 6: 329–339.Google Scholar

Jirsch, J., Hirsch, L.J.. Nonconvulsive seizures: developing a rational approach to the diagnosis and management in the critically ill population. Clinical Neurophysiology 2007; 118: 1660–1670.Google Scholar

McBride, A.E., Shih, T.T., Hirsch, L.J.. Video-EEG monitoring in the elderly: a review of 94 patients. Epilepsia 2002; 43: 165.Google Scholar

Rowan, A.J., Ramsay, R.E., Collins, J.F., et al. New onset geriatric epilepsy: a randomized study of gabapentin, lamotrigine, and carbamazepine. Neurology 2005; 64: 1868–1873.Google Scholar

Cumbo, E., Ligori, L.D.. Levitiracetam, lamotrigine, and phenobarbital in patients with epileptic seizures and Alzheimer’s disease. Epilepsy Behavior 2010; 17: 461.Google Scholar

Glauser, T., Ben-Menachem, E., Bourgeois, B., et al. ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 2006; 47: 1094–1120.Google Scholar

Glauser, T., Ben-Menachem, E., Bourgeois, B., et al. Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 2013; 54: 551–563.Google Scholar

Speechio, L.M., Tramacere, L., La Neve, A., Beghi, E.. Discontinuing antiepileptic drugs in patients who are seizure free on monotherapy. J Neurol, Neurosurg Psychiatry 2002; 72: 22–25.Google Scholar

Robbins, M.S., Lipton, R.B.. Management of headache in the elderly. Drugs Aging 2010; 27: 377–398.Google Scholar

Schwaiger, J., Kiechl, S., Seppi, K., et al. Prevalence of primary headaches and cranial neuralgias in men and women aged 55–94 years (Bruneck Study). Cephalagia 2009; 29: 179–187.Google Scholar

Walker, R.A., Wadman, M.C.. Headache in the elderly. Clin Geriatr Med 2007; 23: 291–305.Google Scholar

Prencipe, M., Casini, A., Ferretti, C., et al. Prevalence of headache in an elderly population: attack frequency, disability and use of medication. J Neurol Neurosurg Psychiatry 2001; 70: 377–81.Google Scholar

Pringsheim, T., Davenport, J., Becker, W.. Prophylaxis of migraine headache. CMAJ 2010; 182: E269–276.Google Scholar

Charles, A.. The evolution of a migraine attack – a review of recent evidence. Headache 2013; 53: 413–419.Google Scholar

Bamford, C.C., Mays, M., Tepper, S.J.. Unusual headaches in the elderly. Curr Pain Headache Rep 2011; 15: 295–301.Google Scholar

Özge, A.. Chronic daily headache in the elderly. Curr Pain Headache Rep 2013; 17: 382–389.Google Scholar

Weyand, C.M., Goronzy, J.J.. Giant-cell arteritis and polymalgia rheumatica. N Engl J Med 2014; 371: 50–57Google Scholar

Kermani, T.A., Schmidt, J.S., Crowson, C.S., et al. Utility of erythrocyte sedimentation rate and C-reactive protein for the diagnosis of giant cell arteritis. Semin Arthritis Rheum 2012; 41: 866–871.Google Scholar

Kristoffersen, E.S., Lundqvist, C.. Medication-overuse headache: epidemiology, diagnosis and treatment. TherAdv Drug Saf. 2014; 5: 87–99.Google Scholar

Dodick, D.W., Capobianco, D.J.. Headaches. In: Sirven, J.I., Malamut, B.L., eds. Clinical Neurology of the Older Adult. 2nd Edition. Philadelphia, Lippincott Williams and Wilkins, 2008; 197–212.Google Scholar

Feigin, VL, Lawes, CM, Bennett, DA, Anderson, CS. Stroke epidemiology: a review of population-based studies of incidence, prevalence, and case-fatality in the late 20th century. Lancet Neurol 2003 Jan;2(1):43–53.Google Scholar

Koton, S, Schneider, AL, Rosamond, WD, et al. Stroke incidence and mortality trends in US communities, 1987 to 2011. JAMA 2014 Jul 16;312(3):259–268.Google Scholar

Go, AS, Mozaffarian, D, Roger, VL, et al. Executive summary: heart disease and stroke statistics–2014 update: a report from the American Heart Association. Circulation 2014 Jan 21;129(3):399–410.Google Scholar

Yusuf, S, Rangarajan, S, Teo, K, et al. Cardiovascular risk and events in 17 low-, middle-, and high-income countries. N Engl J Med 2014 Aug 28;371(9):818–827.Google Scholar

Sacco, RL, Kasner, SE, Broderick, JP, et al. An updated definition of stroke for the 21st century: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2013 Jul;44(7):2064–2089.Google Scholar

Marini, C, Baldassarre, M, Russo, T, et al. Burden of first-ever ischemic stroke in the oldest old: evidence from a population-based study. Neurology 2004 Jan 13;62(1):77–81.Google Scholar

Burke, JF, Freedman, VA, Lisabeth, LD, et al. Racial differences in disability after stroke: results from a nationwide study. Neurology 2014 Jul 29;83(5):390–397.Google Scholar

Kelly, AG, Hoskins, KD, Holloway, RG. Early stroke mortality, patient preferences, and the withdrawal of care bias. Neurology 2012 Aug 28;79(9):941–944.Google Scholar

Qureshi, AI, Chaudhry, SA, Connelly, B, et al. Impact of advanced healthcare directives on treatment decisions by physicians in patients with acute stroke. Crit Care Med 2013 Jun;41(6):1468–1475.Google Scholar

Silveira, MJ, Wiitala, W, Piette, J. Advance directive completion by elderly Americans: a decade of change. J Am Geriatr Soc 2014 Apr;62(4):706–710.Google Scholar

Barber, PA, Kleinig, TJ. INTERACT2: a reason for optimism with spontaneous intracerebral hemorrhage? Int J Stroke 2014 Jan;9(1):59–60.Google Scholar

McArdle, PF, Kittner, SJ, Ay, H, et al. Agreement between TOAST and CCS ischemic stroke classification: The NINDS SIGN Study. Neurology 2014 Oct 28;83(18):1653–1660. Epub 2014 Sep 26.Google Scholar

Adams, HP Jr, Bendixen, BH, Kappelle, LJ, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993 Jan;24(1):35–41.Google Scholar

Arsava, EM, Ballabio, E, Benner, T, et al. The Causative Classification of Stroke system: an international reliability and optimization study. Neurology 2010 Oct 5;75(14):1277–1284.Google Scholar

Asimos, AW, Johnson, AM, Rosamond, WD, et al. A multicenter evaluation of the ABCD2 score’s accuracy for predicting early ischemic stroke in admitted patients with transient ischemic attack. Ann Emerg Med 2010 Feb;55(2):201–210.e5.Google Scholar

Easton, JD, Saver, JL, Albers, GW, et al. Definition and evaluation of transient ischemic attack: a scientific statement for healthcare professionals from the American Heart Association/American Stroke Association Stroke Council; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular Nursing; and the Interdisciplinary Council on Peripheral Vascular Disease. The American Academy of Neurology affirms the value of this statement as an educational tool for neurologists. Stroke 2009 Jun;40(6):2276–2293.Google Scholar

Giles, MF, Albers, GW, Amarenco, P, et al. Early stroke risk and ABCD2 score performance in tissue- vs time-defined TIA: a multicenter study. Neurology 2011 Sep 27;77(13):1222–1228.Google Scholar

Kleindorfer, D, Panagos, P, Pancioli, A, et al. Incidence and short-term prognosis of transient ischemic attack in a population-based study. Stroke 2005 Apr;36(4):720–723.Google Scholar

Johnston, SC, Gress, DR, Browner, WS, Sidney, S. Short-term prognosis after emergency department diagnosis of TIA. JAMA 2000 Dec 13;284(22):2901–2906.Google Scholar

Rojas, JI, Zurru, MC, Romano, M, et al. Acute ischemic stroke in patients aged 80 or older. Medicina (B Aires) 2007;67(6 Pt 2):701–704.Google Scholar

Agyemang, C, van Oeffelen, AA, Norredam, M, et al. Ethnic disparities in ischemic stroke, intracerebral hemorrhage, and subarachnoid hemorrhage incidence in the Netherlands. Stroke 2014 Sep 30;45(11):3236–3242.Google Scholar

Talahma, M, Strbian, D, Sundararajan, S. Sickle cell disease and stroke. Stroke 2014 Jun;45(6):e98–e100.Google Scholar

Gueguen, A, Mahevas, M, Nzouakou, R, et al. Sickle-cell disease stroke throughout life: a retrospective study in an adult referral center. Am J Hematol 2014 Mar;89(3):267–272.Google Scholar

Tinetti, ME, Han, L, Lee, DS, et al. Antihypertensive medications and serious fall injuries in a nationally representative sample of older adults. JAMA Intern Med 2014 Apr;174(4):588–595.Google Scholar

Aronow, WS, Fleg, JL, Pepine, CJ, et al. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension. J Am Soc Hypertens 2011 Jul–Aug;5(4):259–352.Google Scholar

Gouya, G, Arrich, J, Wolzt, M, et al. Antiplatelet treatment for prevention of cerebrovascular events in patients with vascular diseases: a systematic review and meta-analysis. Stroke 2014 Feb;45(2):492–503.Google Scholar

Kernan, WN, Ovbiagele, B, Black, HR, et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2014 Jul;45(7):2160–2236.Google Scholar

Shin, JY, Choi, NK, Jung, SY, et al. Risk of ischemic stroke with the use of risperidone, quetiapine and olanzapine in elderly patients: a population-based, case-crossover study. J Psychopharmacol 2013 Jul;27(7):638–644.Google Scholar

Everson-Rose, SA, Roetker, NS, Lutsey, PL, et al. Chronic stress, depressive symptoms, anger, hostility, and risk of stroke and transient ischemic attack in the multi-ethnic study of atherosclerosis. Stroke 2014 Aug;45(8):2318–2323.Google Scholar

Lambiase, MJ, Kubzansky, LD, Thurston, RC. Prospective study of anxiety and incident stroke. Stroke 2014 Feb;45(2):438–443.Google Scholar

Helms, TM, Duong, G, Zippel-Schultz, B, et al. Prediction and personalised treatment of atrial fibrillation-stroke prevention: consolidated position paper of CVD professionals. EPMA J 2014 Sep 2;5(1):15.Google Scholar

Coppens, M, Hart, RG, Eikelboom, JW. Stroke prevention in older adults with atrial fibrillation. CMAJ 2013 Nov 19;185(17):1479–1480.Google Scholar

Quinn, GR, Fang, MC. Atrial fibrillation: stroke prevention in older adults. Clin Geriatr Med 2012 Nov;28(4):617–634.Google Scholar

Moran, PS, Flattery, MJ, Teljeur, C, et al. Effectiveness of systematic screening for the detection of atrial fibrillation. Cochrane Database Syst Rev 2013 Apr 30;4:CD009586.Google Scholar

Sanna, T, Diener, HC, Passman, RS, et al. Cryptogenic stroke and underlying atrial fibrillation. N Engl J Med 2014 Jun 26;370(26):2478–2486.Google Scholar

Gladstone, DJ, Spring, M, Dorian, P, et al. Atrial fibrillation in patients with cryptogenic stroke. N Engl J Med 2014 Jun 26;370(26):2467–2477.Google Scholar

Weber-Kruger, M, Gelbrich, G, Stahrenberg, R, et al. Finding atrial fibrillation in stroke patients: randomized evaluation of enhanced and prolonged Holter monitoring – Find-AF_RANDOMISED – rationale and design. Am Heart J 2014 Oct;168(4):438–445.e1.Google Scholar

Halperin, JL, Hankey, GJ, Wojdyla, DM, et al. Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). Circulation 2014 Jul 8;130(2):138–146.Google Scholar

Sardar, P, Chatterjee, S, Chaudhari, S, Lip, GY. New oral anticoagulants in elderly adults: evidence from a meta-analysis of randomized trials. J Am Geriatr Soc 2014 May;62(5):857–864.Google Scholar

Dzik, WS. Reversal of drug-induced anticoagulation: old solutions and new problems. Transfusion 2012 May;52 Suppl 1:45S–55S.Google Scholar

Salvi, F, Marchetti, A, D’Angelo, F, et al. Adverse drug events as a cause of hospitalization in older adults. Drug Saf 2012 Jan;35 Suppl 1:29–45.Google Scholar

Wang, C, Yi, X, Zhang, B, et al. Clopidogrel plus aspirin prevents early neurologic deterioration and improves 6-month outcome in patients with acute large artery atherosclerosis stroke. Clin Appl Thromb Hemost 2015 Jul;21(5):453–461. Epub 2014 Sep 23.Google Scholar

Wong, KS, Chen, C, Fu, J, et al. Clopidogrel plus aspirin versus aspirin alone for reducing embolisation in patients with acute symptomatic cerebral or carotid artery stenosis (CLAIR study): a randomised, open-label, blinded-endpoint trial. Lancet Neurol 2010 May;9(5):489–497.Google Scholar

Markus, HS, Droste, DW, Kaps, M, et al. Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic carotid stenosis evaluated using doppler embolic signal detection: the clopidogrel and aspirin for reduction of emboli in symptomatic carotid stenosis (CARESS) trial. Circulation 2005 May 3;111(17):2233–2240.Google Scholar

Boan, AD, Lackland, DT, Ovbiagele, B. Lowering of blood pressure for recurrent stroke prevention. Stroke 2014 Aug;45(8):2506–2513.Google Scholar

De Lima, LG, Saconato, H, Atallah, AN, da Silva, EM. Beta-blockers for preventing stroke recurrence. Cochrane Database Syst Rev 2014 Oct 15;10:CD007890.Google Scholar

Udell, JA, Opotowsky, AR, Khairy, P, et al. Patent foramen ovale closure vs medical therapy for stroke prevention: meta-analysis of randomized trials and review of heterogeneity in meta-analyses. Can J Cardiol 2014 Oct;30(10):1216–1224.Google Scholar

Kmietowicz, Z. Geriatrician questions prescribing for stroke prevention in people over 80. BMJ 2014 Feb 26;348:g1788.Google Scholar

Byatt, K. Overenthusiastic stroke risk factor modification in the over-80s: are we being disingenuous to ourselves, and to our oldest patients? Evid Based Med 2014 Aug;19(4):121–122.Google Scholar

Manocha, D, Bansal, N, Gumaste, P, Brangman, S. Safety profile of high-dose statin therapy in geriatric patients with stroke. South Med J 2013 Dec;106(12):658–664.Google Scholar

Raley, KA, Hutchison, AM. Statin use and cognitive changes in elderly patients with dementia. Consult Pharm 2014;29(7):487–489.Google Scholar

Mandas, A, Congiu, MG, Abete, C, et al. Cognitive decline and depressive symptoms in late-life are associated with statin use: evidence from a population-based study of Sardinian old people living in their own home. Neurol Res 2014 Mar;36(3):247–254.Google Scholar

Tapia-Perez, JH, Gehring, S, Zilke, R, Schneider, T. Effect of increased glucose levels on short-term outcome in hypertensive spontaneous intracerebral hemorrhage. Clin Neurol Neurosurg 2014 Mar;118:37–43.Google Scholar

Tanaka, R, Ueno, Y, Miyamoto, N, et al. Impact of diabetes and prediabetes on the short-term prognosis in patients with acute ischemic stroke. J Neurol Sci 2013 Sep 15;332(1–2):45–50.Google Scholar

Nardi, K, Milia, P, Eusebi, P, et al. Predictive value of admission blood glucose level on short-term mortality in acute cerebral ischemia. J Diabetes Complications 2012 Mar–Apr;26(2):70–76.Google Scholar

Murphy, RA, Patel, KV, Kritchevsky, SB, et al. Weight change, body composition, and risk of mobility disability and mortality in older adults: a population-based cohort study. J Am Geriatr Soc 2014 Aug;62(8):1476–1483.Google Scholar

Alamowitch, S, Eliasziw, M, Algra, A, et al. Risk, causes, and prevention of ischaemic stroke in elderly patients with symptomatic internal-carotid-artery stenosis. Lancet 2001 Apr 14;357(9263):1154–1160.Google Scholar

Brott, TG, Hobson, RW 2nd, Howard, G, et al. Stenting versus endarterectomy for treatment of carotid-artery stenosis. N Engl J Med 2010 Jul 1;363(1):11–23.Google Scholar